|
|
| | Lipid N2-3L Basic information |
| Product Name: | Lipid N2-3L | | Synonyms: | Lipid N2-3L;9-Octadecenoic acid (9Z)-, 3-[2-[(2-hexyl-1-oxodecyl)oxy]ethyl]-14-hydroxy-12-(2-hydroxyethyl)-7-oxo-6-oxa-3,8,12-triazatetradec-1-yl ester | | CAS: | 2924606-55-1 | | MF: | C48H93N3O8 | | MW: | 840.27 | | EINECS: | | | Product Categories: | | | Mol File: | 2924606-55-1.mol |  |
| | Lipid N2-3L Chemical Properties |
| Boiling point | 838.859±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 0.996±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | solubility | DMSO: Soluble: =10 mg/ml
Ethanol: Soluble: =10 mg/ml | | pka | 12.650±0.46(predicted) |
| | Lipid N2-3L Usage And Synthesis |
| Description | Lipid N2-3L is an ionizable cationic lipid (pKa = 8.99) that has been used in the generation of supramolecular lipid nanoparticles (SMLNPs) encapsulating mRNA for use in vitro and in vivo.1 SMLNPs containing lipid N2-3L and encapsulating a luciferase reporter accumulate at the site of injection and in the draining lymph nodes of mice. Lipid N2-3L-containing SMLNPs encapsulating ovalbumin mRNA and the toll-like receptor 7/8 (TLR7/8) agonist R-848 (Item No. 14806) as an adjuvant promote dendritic cell maturation and antigen presentation, reduce tumor volume, and increase survival in an MC-38-OVA murine model of colon cancer.WARNING This product is not for human or veterinary use. | | References | [1] SHAOLONG QI. Supramolecular Lipid Nanoparticles Based on Host–Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy[J]. Advanced Materials, 2024, 36 23. DOI: 10.1002/adma.202311574 |
| | Lipid N2-3L Preparation Products And Raw materials |
|